Loxo Oncology, Inc. Announces Board Appointments
Oct 3 13
Loxo Oncology, Inc. announced that it has completed a $33 million Series A financing round. The round included founding investor Aisling Capital and new investors OrbiMed Advisors LLC and an undisclosed investor. In conjunction with the financing, the company announced Keith Flaherty, M.D., director of the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital to its Board of Directors. Additionally, Loxo Oncology appointed four new members to its Scientific Advisory Board. These nationally-recognized physician/scientists are providing critical advice and expertise to the company around rational target selection, product profile definition and clinical development strategy. In addition to Dr. Flaherty, who is chair of the Scientific Advisory Board, the new members include: Jeffrey A. Engelman, M.D., Ph.D., director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center; associate professor of Medicine, Harvard Medical School. Ross L. Levine, M.D., associate member, Human Oncology and Pathogenesis Program, and associate attending physician, Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center; associate professor of Medicine, Weill Cornell Medical College. Ben Ho Park, M.D., Ph.D., associate professor of Oncology, Breast Cancer Research Program, and Joint Appointment, Whiting School of Engineering, Department of Chemical and Biomolecular Engineering, Johns Hopkins University; attending physician, Johns Hopkins Hospital, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. David Solit, M.D., Ph.D., director, Developmental Therapeutics, and associate professor of Medicine, Cell and Developmental Biology, Memorial Sloan-Kettering Cancer Center.
Array BioPharma and Loxo Oncology Announce a Multi-Year Licence and Collaboration Agreement for the Development of a Pre-Clinical Drug Candidate Geared
Jul 11 13
Array BioPharma and Loxo Oncology have announced a multi-year licence and collaboration agreement for the development of a pre-clinical drug candidate geared against an oncogenic mutation that was developed by Array. In addition, the two companies will collaborate on discovery and development of other molecules for oncology targets in well-defined target populations. Based on the agreement, Loxo will be responsible for target selection on candidates by utilising Array's pre-clinical drug discovery platform and research capabilities and will consequently resume clinical development of selected targets. Array is eligible for USD 434 million from milestone payments, an undisclosed number of shares of Loxo stock, and will receive royalties on sales of approved products.
Loxo Oncology, Inc. and Array BioPharma, Inc. Announces a Multi-Year License and Collaboration Agreement
Jul 10 13
Loxo Oncology, Inc. and Array BioPharma Inc. announced a multi-year license and collaboration agreement for an Array-invented preclinical development candidate and related intellectual property. In addition, Loxo and Array will collaborate to discover and develop small molecule drugs for mutually agreed upon novel oncology targets. The licensed program targets a specified novel oncogenic activating mutation. This program and collaboration benefit from recent advances in understanding the cancer genome. For novel, driver oncogenes, it is possible to accelerate both preclinical and clinical development of compounds in well-defined target populations. To date, this approach has generated robust response rates in Phase 1 and 2 trials, which in turn has enabled rapid clinical development and commercialization. Under the terms of the agreement, Loxo will fund Array's preclinical research, providing access to Array's world-class discovery platform and scientists, and will be responsible for target selection and conducting clinical trials.